Aggressive Lymphomas
Conference Coverage
Single-agent acalabrutinib ‘impressive’ in patients with WM
CHICAGO—Acalabrutinib monotherapy was highly effective in Waldenström’s macroglobulinemia (WM) in a phase 2 study, investigator Roger Owen, MD,...
From the Journals
Overcoming TP53 mutation proves difficult in MCL
A new study shows disappointing results for the addition of lenalidomide to chemoimmunotherapy regimens.
News
Older, cheaper drug formulation to remain available
The 140 mg capsules of Imbruvica® (ibrutinib) will remain on the market, according to Pharmacyclics LLC. Pharmacyclics (an AbbVie company) and...
Conference Coverage
Pediatric cancers are on the rise
PITTSBURGH – CDC investigators detected a significant increase in pediatric cancers from 2001 through 2014, although the reasons for the rise are...
From the Journals
Adding bortezomib does not improve MCL outcomes
The addition of bortezomib is a bust in patients with newly diagnosed mantle cell lymphoma.
News
Umbralisib has ‘distinct’ safety profile
Phase 1 trial results suggest umbralisib, a PI3Kδ/CK1ε inhibitor, can be safe and active in patients with relapsed or refractory B-cell...
From the Journals
Study: No link between non-Hodgkin lymphoma and Q fever
The study looks at the incidence of non-Hodgkin lymphoma in the Netherlands before, during, and after a Q fever epidemic.
News
‘Long-term benefits’ with nivolumab in cHL
Nivolumab can provide “long-term benefits” in patients with relapsed or refractory classical Hodgkin lymphoma (cHL), according to researchers....
News
Drug granted fast track designations for FL, DLBCL
The US Food and Drug Administration (FDA) has granted 2 fast track designations to 5F9, an anti-CD47 antibody. The designations are for 5F9 as a...
News
Novartis CAR T-cell therapy adds a lymphoma indication
The new approval puts tisagenlecleucel head to head with Gilead’s axicabtagene ciloleucel.
News
FDA issues CRL for proposed biosimilar rituximab
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) saying the agency cannot approve Sandoz’s proposed...